Phase 2 study of LY2484595 with statins in hypercholesterolemia or low HDL-C

Phase 2, randomised, double-blind trial of evacetrapib in hypercholesterolemia and Hypo-HDL cholesterolemia (HALP) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percent change in HDL-C from baseline to 12 weeks and Percent change in LDL-C from baseline to 12 weeks. Started Apr 2010; status: completed.